Response Times in Danish Emergency Medical Services
Launched by PETER MARTIN HANSEN · Oct 29, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking into how the time it takes for emergency medical services, like ambulances and helicopters, to reach patients impacts their chances of survival and recovery. The researchers will gather information from patients in Denmark who needed emergency help between 2016 and 2022. They want to see if quicker response times lead to better outcomes, such as fewer days in the intensive care unit.
If you or a loved one received emergency medical services during this time and were treated with lights and sirens or without them, you might be eligible to be part of this study. Participants can expect that their treatment journey will be followed from the moment of their illness or injury until they leave the hospital. This study aims to provide valuable insights that could improve emergency care for everyone in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Every patient in Denmark in need of ambulance and/or helicopter services treatment in Denmark from 2016-2022 with outgoing response mode A (with lights and sirens) and B (without lights and sirens) is eligible for inclusion in the study.
- Exclusion Criteria:
- • No civil personal registration number available
- • Patient not identified
- • Patient not entered in the prehospital electronic patient journal
- • invalid data entered
- • No linkage between substitue personal register number and actual personal register number for patients identified later;
About Peter Martin Hansen
Peter Martin Hansen is a distinguished clinical trial sponsor dedicated to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, the organization collaborates with leading researchers and institutions to conduct rigorous clinical trials across various therapeutic areas. Committed to upholding the highest ethical standards and regulatory compliance, Peter Martin Hansen prioritizes patient safety and data integrity, ensuring that all studies are designed and executed with precision. Through its comprehensive approach to clinical development, the sponsor aims to contribute meaningful advancements to healthcare and facilitate the discovery of new treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Odense, , Denmark
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported